|
Search
Collections
Benchmarks
Upload document
Indication
Clear Cell Kidney Carcinoma
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 clinical trial
1 product
Clinical trial
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic), Confirmed Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF), for Whom Standard Systemic Therapy Has Failed or Progressed, in Whom There Are no Satisfactory Treatment Alternatives and Who Are Not Eligible for Other Clinical Trials.
Status:
Product
Axitinib